首页> 外国专利> METHODS FOR TREATING NEOPLASTIC, ANGIOGENIC, FIBROPLASTIC, AND/OR IMMUNOSUPPRESIVE OCULAR IRREGULARITIES VIA ADMINISTRATION OF METHOTREXATE BASED MEDICAMENTS, AND OCULAR IONTOPHORETIC DEVICES FOR DELIVERING METHOTREXATE BASED MEDICAMENTS

METHODS FOR TREATING NEOPLASTIC, ANGIOGENIC, FIBROPLASTIC, AND/OR IMMUNOSUPPRESIVE OCULAR IRREGULARITIES VIA ADMINISTRATION OF METHOTREXATE BASED MEDICAMENTS, AND OCULAR IONTOPHORETIC DEVICES FOR DELIVERING METHOTREXATE BASED MEDICAMENTS

机译:通过基于甲氨蝶呤的药物的管理以及用于递送基于甲氨蝶呤的药物的眼电离子设备来治疗新陈代谢,血管生成,成纤维细胞和/或免疫抑制性眼不规则的方法

摘要

A method for treating neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularities of a living subject, comprising the steps of: providing a living subject, wherein the living subject includes an affected ocular area having a neoplastic, angiogenic, fibroblastic, and/or immunosuppressive irregularity; providing a methotrexate based medicament, wherein the methotrexate based medicament is capable of inhibiting DNA synthesis; associating a therapeutically effective concentration of the methotrexate based medicament with the affected ocular area of the living subject; and decreasing the neoplastic, angiogenic, fibroblastic, and/or immunosuppressive ocular irregularity of the living subject.
机译:一种用于治疗活体的赘生性,血管生成,成纤维细胞和/或免疫抑制性眼不规则的方法,包括以下步骤:提供活体,其中所述活体包括具有赘生性,血管生成,成纤维细胞和/或/的患眼区域。或免疫抑制异常;提供基于甲氨蝶呤的药物,其中基于甲氨蝶呤的药物能够抑制DNA合成;使基于甲氨蝶呤的药物的治疗有效浓度与活对象的受影响眼区域相关联;和减少活体的肿瘤,血管生成,成纤维细胞和/或免疫抑制性眼部不规则。

著录项

  • 公开/公告号EP1443931A1

    专利类型

  • 公开/公告日2004-08-11

    原文格式PDF

  • 申请/专利权人 IOMED INC.;

    申请/专利号EP20020752438

  • 发明设计人 WARREN STEPHEN;HAMILTON STEVEN;

    申请日2002-07-19

  • 分类号A61K31/50;

  • 国家 EP

  • 入库时间 2022-08-21 22:51:45

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号